Search

everythinglearnresearchcommunity

for

Search:↓

Lipid Accumulation Product and Free Androgens Index are effective for assessing fatty liver disease risk in women with Polycystic Ovary Syndrome.

Current methods for grading hair loss from cancer treatment are not accurate enough and need improvement.

The updated GRADE guidance advises considering context when interpreting variability in research results and introduces tools for assessing subgroup effects.

Tailoring COVID-19 measures to risk levels in the military improves health and readiness.

Risk analysis is important for safely adjusting pharmaceutical formulas while maintaining their quality and effectiveness.

Higher air pollution increases the risk of alopecia areata.

The document's conclusion cannot be provided because the content is not accessible.

rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.

Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.

The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

The DLQI is a key tool for measuring quality of life in dermatology.

rwSALT provides precise hair regrowth measurement from scalp photos.

The G allele of IFITM3 rs12252 is linked to more severe COVID-19.

The DLQI is reliable but may not fully capture the impact of skin conditions on quality of life, especially in emotional and psychological areas.

Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.

Women with premature ovarian insufficiency have a worse cardiovascular risk profile than premenopausal women.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Hair restoration surgery has a growing risk of hair loss over time.

Public health decisions should rely on independent trials, not biased literature.

The Spanish version of the Hair Specific Skindex-29 scale is a reliable and valid way to measure the impact of hair loss on women's quality of life.

The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.

Detecting early breast arterial calcifications can help assess cardiovascular disease risk.

The "exposure–crossover design" helps assess individual changes in risk after events like car crashes.

The Dermatology Life Quality Index is reliable and consistent but needs more diverse participant studies.

Early intervention is important for limited systemic sclerosis patients due to higher pain and ulceration risks.

A standardized scoring system is needed to improve model reliability for predicting hair loss in brain tumor patients treated with proton therapy.

A new tool simplifies alopecia areata severity scoring but needs validation.

There is a significant need for better-validated quality of life tools in dermatology.